Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
June 20, 2026Current Cancer Drug Targets

CDK Inhibition in Lung Cancer Alters Epithelial–Mesenchymal Transition,Autophagy, and Metabolism

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAzizeh AlsayyidRGRose GhemrawiNSNour Sammani

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates CDK inhibitors to affect cell behavior in lung adenocarcinoma, suggesting new treatment avenues.

Key Points

  • This research aims to explore the role of CDK1, CDK2, CDK5, CDK7, and CDK9 in lung adenocarcinoma and assess the effects of specific CDK inhibitors.
  • Gene expression levels analyzed using the UALCAN tool on TCGA LUAD dataset.
  • A549 and H292 cell lines treated with Roscovitine and RO-3306 to assess viability and migration.
  • Western blotting used to evaluate protein expression related to autophagy and epithelial-to-mesenchymal transition.
  • Significant overexpression of CDK1, CDK2, CDK5, CDK7, and CDK9 observed in LUAD.
  • Roscovitine showed greater potency in reducing cell viability and promoting E-cadherin, reversing epithelial-to-mesenchymal transition.
  • Roscovitine induced complete autophagy, while RO-3306 had limited effects on migration and incomplete autophagic response.

Cite This Study

Alsayyid et al. (2026) studied this question.

synapsesocial.com/papers/6a3631a1db0793dc1a538642https://doi.org/10.2174/0115680096414298251201033358
View Full Paper
Ask AI
Bookmark
Share